Vitamin D Receptor And Paclitaxel In Triple Negative Breast Cancer: Is There A Link Between Them?

GUEVARA JA; IBARRA AA; QUEVEDO A; ALONSO E; COLÓ GP; FACCHINETTI MM; FERRONATO MJ; CURINO AC

Congreso; LXVI Reunión Anual de la Sociedad Argentina de Investigación Clínica (SAIC).; 2021

Sociedad Argentina de Investigación Clinica

Paclitaxel (PTX) is an antitumor agent employed in the treatment of Triple-Negative Breast Cancer (TNBC). TNBC expresses Vitamin D Receptor (VDR), a member of the nuclear receptor superfamily. The aim of this work was to investigate the involvement of VDR in the antitumor action of PTX in TNBC cells. To this end, viability assays by crystal violet staining were performed in murine 4T1 TNBC cells and in 4T1 stably expressing a shRNA against VDR (4T1 shVDR), treated with PTX (10 nM) or vehicle. Also, cell cycle was studied by flow cytometry. Cellular studies were complemented with in silico analyses including molecular docking and molecular dynamics (MD) simulations to describe the pharmacodynamic interaction between PTX and VDR. The results show that PTX reduced the viability of 4T1 wild type cells (p